Clinical trial NCT06305754: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Official title: A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Non-small Cell Lung Cancer (NSCLC)
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2024-03-12
Enrollment: 520
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).

The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).

Detailed description: Participants will be randomized 1:1 into two arms:

* Sacituzumab tirumotecan
* Pemetrexed plus Carboplatin

Participants will receive treatment until any of the criteria for discontinuation of study intervention are met.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).
* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.
* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
* Life expectancy of at least 3 months.

Exclusion Criteria:

* Predominantly squamous cell histology NSCLC.
* History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
* Grade ≥2 peripheral neuropathy.
* History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
* Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
* Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
* Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention.
* Known active central nervous system metastases and/or carcinomatous meningitis.
* Active infection requiring systemic therapy.
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* Concurrent active HBV and HCV infection.
* History of allogeneic tissue/solid organ transplant.
* Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Primary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: Up to approximately 51 months
measure: Overall Survival (OS)
timeFrame: Up to approximately 51 months
Secondary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: Up to approximately 51 months
measure: Duration of Response (DOR)
timeFrame: Up to approximately 51 months
measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
timeFrame: Baseline and up to approximately 6 years
measure: Change From Baseline in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30
timeFrame: Baseline and up to approximately 6 years
measure: Change from Baseline in the Cough (Item 31) Score, on the EORTC Lung-Cancer specific Quality of Life Questionnaire (QLQ-LC13)
timeFrame: Baseline and up to approximately 6 years
measure: Change from Baseline in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13
timeFrame: Baseline and up to approximately 6 years
measure: Time to Deterioration (TTD) in Global Health Status/Quality of Life (Items 29 and 30) Combined Score, on the EORTC QLQ-C30
timeFrame: Baseline and up to approximately 6 years
measure: TTD in the Dyspnea (Item 8) Score, on the EORTC QLQ-C30
timeFrame: Baseline and up to approximately 6 years
measure: TTD in the Cough (Item 31) Score, on the EORTC QLQ-LC13
timeFrame: Baseline and up to approximately 6 years
measure: TTD in the Chest Pain (Item 40) Score, on the EORTC QLQ-LC13
timeFrame: Baseline and up to approximately 6 years
measure: Number of Participants Who Experience One or More Adverse Events (AEs)
timeFrame: Up to approximately 6 years
measure: Number of Participants Who Discontinue Study Treatment Due to an AE
timeFrame: Up to approximately 6 years
Other outcomes:
Locations:
city: Oakland
country: United States
facility: Kaiser Permanente - Oakland ( Site 0054)
state: California
city: Roseville
country: United States
facility: Kaiser Permanente - Roseville ( Site 0055)
state: California
city: San Francisco
country: United States
facility: Kaiser Permanente - San Francisco ( Site 0056)
state: California
city: Santa Clara
country: United States
facility: Kaiser Permanente - Santa Clara ( Site 0057)
state: California
city: Vallejo
country: United States
facility: Kaiser Permanente-Kaiser Permanente ( Site 0036)
state: California
city: Walnut Creek
country: United States
facility: Kaiser Permanente - Walnut Creek ( Site 0058)
state: California
city: Orange City
country: United States
facility: Mid Florida Hematology and Oncology Center ( Site 0005)
state: Florida
city: Marietta
country: United States
facility: Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003)
state: Georgia
city: Ann Arbor
country: United States
facility: University of Michigan ( Site 0009)
state: Michigan
city: Springfield
country: United States
facility: Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051)
state: Missouri
city: East Brunswick
country: United States
facility: Astera Cancer Care ( Site 0032)
state: New Jersey
city: Stony Brook
country: United States
facility: Stony Brook University-Cancer Center ( Site 0038)
state: New York
city: Fargo
country: United States
facility: Sanford Fargo Medical Center ( Site 0028)
state: North Dakota
city: Sioux Falls
country: United States
facility: Sanford Cancer Center ( Site 0024)
state: South Dakota
city: Houston
country: United States
facility: Millennium Research & Clinical Development ( Site 0035)
state: Texas
city: Caba.
country: Argentina
facility: Clinica Adventista Belgrano-Oncology ( Site 0315)
state: Buenos Aires
city: Ciudad Autónoma de Buenos Aires
country: Argentina
facility: Instituto Alexander Fleming ( Site 0307)
state: Buenos Aires
city: Ciudad autónoma de Buenos Aires
country: Argentina
facility: Hospital Británico de Buenos Aires-Oncology ( Site 0304)
state: Caba
city: Río Cuarto
country: Argentina
facility: Centro Privado de RMI Río Cuarto S.A. II ( Site 0310)
state: Cordoba
city: Rosario
country: Argentina
facility: Instituto de Oncología de Rosario ( Site 0301)
state: Santa Fe
city: La Rioja
country: Argentina
facility: Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0303)
city: Edmonton
country: Canada
facility: Cross Cancer Institute ( Site 0201)
state: Alberta
city: Kitchener
country: Canada
facility: Waterloo Regional Health Network (WRHN) ( Site 0207)
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre ( Site 0203)
state: Ontario
city: Montréal
country: Canada
facility: McGill University Health Centre ( Site 0204)
state: Quebec
city: Hefei
country: China
facility: Anhui Provincial Cancer Hospital ( Site 3132)
state: Anhui
city: Beijing
country: China
facility: Beijing Cancer hospital ( Site 3100)
state: Beijing
city: Beijing
country: China
facility: Beijing Peking Union Medical College Hospital-pneumology department ( Site 3107)
state: Beijing
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital-Medical Oncology ( Site 3128)
state: Chongqing
city: Fuzhou
country: China
facility: Fujian Cancer Hospital ( Site 3124)
state: Fujian
city: XiaMen
country: China
facility: The First Affiliated hospital of Xiamen University ( Site 3125)
state: Fujian
city: Guangzhou
country: China
facility: Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 3102)
state: Guangdong
city: Nanning
country: China
facility: Guangxi Medical University Affiliated Tumor Hospital-Respiratory Oncology ( Site 3103)
state: Guangxi
city: Harbin
country: China
facility: Harbin Medical University Cancer Hospital ( Site 3109)
state: Heilongjiang
city: Zhengzhou
country: China
facility: Henan Cancer Hospital ( Site 3105)
state: Henan
city: Wuhan
country: China
facility: Tongji Hospital Tongji Medical,Science & Technology ( Site 3121)
state: Hubei
city: Wuhan
country: China
facility: Hubei Cancer Hospital ( Site 3122)
state: Hubei
city: Changsha
country: China
facility: The Second Xiangya Hospital of Central South University-Oncology ( Site 3104)
state: Hunan
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 3117)
state: Jiangsu
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University-Respiratory Department ( Site 3118)
state: Jiangsu
city: Nanchang
country: China
facility: The Second Affiliated Hospital of Nanchang University ( Site 3119)
state: Jiangxi
city: XI An
country: China
facility: The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 3130)
state: Shaanxi
city: Jinan
country: China
facility: Jinan Central Hospital ( Site 3113)
state: Shandong
city: Jinan
country: China
facility: Shandong Cancer Hospital ( Site 3112)
state: Shandong
city: Shanghai
country: China
facility: Zhongshan Hospital of Fudan University ( Site 3133)
state: Shanghai
city: Taiyuan
country: China
facility: Shanxi Cancer Hospital ( Site 3114)
state: Shanxi
city: Cheng Du
country: China
facility: West China Hospital, Sichuan University ( Site 3126)
state: Sichuan
city: Chengdu
country: China
facility: Sichuan Cancer hospital. ( Site 3127)
state: Sichuan
city: Hangzhou
country: China
facility: The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3101)
state: Zhejiang
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 3106)
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 3120)
state: Zhejiang
city: Valledupar
country: Colombia
facility: Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0601)
state: Cesar
city: Monteria
country: Colombia
facility: IMAT S.A.S ( Site 0602)
state: Cordoba
city: Bogota
country: Colombia
facility: FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0600)
state: Distrito Capital De Bogota
city: Bogota
country: Colombia
facility: Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0606)
state: Distrito Capital De Bogota
city: Pereira.
country: Colombia
facility: Oncologos del Occidente ( Site 0604)
state: Risaralda
city: Cali
country: Colombia
facility: Fundacion Valle del Lili- CIC-Oncology CIC ( Site 0605)
state: Valle Del Cauca
city: Strasbourg
country: France
facility: Nouvel Hôpital Civil (NHC) ( Site 1302)
state: Alsace
city: Marseille
country: France
facility: Clinique Clairval ( Site 1306)
state: Bouches-du-Rhone
city: Villejuif
country: France
facility: Gustave Roussy ( Site 1303)
state: Ile-de-France
city: Paris
country: France
facility: Hopitaux Universitaires Paris Centre-Hopital Cochin-Unité d'Oncologie Thoracique ( Site 1304)
city: New Delhi
country: India
facility: All India Institute of Medical Sciences-Department of medical oncology ( Site 3303)
state: Delhi
city: New Delhi
country: India
facility: Indraprastha Apollo Hospitals-APOLLO RESEARCH INNOVATION ( Site 3301)
state: Delhi
city: New Delhi
country: India
facility: Rajiv Gandhi Cancer Institute And Research Centre ( Site 3300)
state: Delhi
city: Gurugram
country: India
facility: Artemis hospital ( Site 3307)
state: Haryana
city: Mumbai
country: India
facility: Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute-Centre for cancer ( Site 3302)
state: Maharashtra
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1803)
state: Lombardia
city: Milan
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800)
state: Lombardia
city: Bari
country: Italy
facility: Instituto Tumori Giovanni Paolo II-SSD Oncologia Medica per la Patologia Toracica ( Site 1802)
state: Puglia
city: Firenze
country: Italy
facility: Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1804)
state: Toscana
city: Roma
country: Italy
facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
city: Toyoake
country: Japan
facility: Fujita Health University Hospital ( Site 3409)
state: Aichi
city: Toon
country: Japan
facility: Ehime University Hospital ( Site 3411)
state: Ehime
city: Fukuoka,
country: Japan
facility: National Hospital Organization Kyushu Cancer Center ( Site 3401)
state: Fukuoka
city: Ota
country: Japan
facility: Gunma Prefectural Cancer Center ( Site 3413)
state: Gunma
city: Kanazawa
country: Japan
facility: Kanazawa University Hospital ( Site 3402)
state: Ishikawa
city: Kawasaki
country: Japan
facility: St. Marianna University Hospital ( Site 3415)
state: Kanagawa
city: Yokohama
country: Japan
facility: Kanagawa Cancer Center ( Site 3416)
state: Kanagawa
city: Natori
country: Japan
facility: Miyagi Cancer Center ( Site 3406)
state: Miyagi
city: Hirakata
country: Japan
facility: Kansai Medical University Hospital ( Site 3414)
state: Osaka
city: Kitaadachi-gun
country: Japan
facility: Saitama Prefectural Cancer Center ( Site 3417)
state: Saitama
city: Sunto-gun
country: Japan
facility: Shizuoka Cancer Center ( Site 3405)
state: Shizuoka
city: Chuo
country: Japan
facility: National Cancer Center Hospital ( Site 3408)
state: Tokyo
city: Ota
country: Japan
facility: Toho University Omori Medical Center ( Site 3407)
state: Tokyo
city: Fukuoka
country: Japan
facility: Kyushu University Hospital ( Site 3400)
city: Hiroshima
country: Japan
facility: Hiroshima City Hiroshima Citizens Hospital ( Site 3419)
city: Niigata
country: Japan
facility: Niigata Cancer Center Hospital ( Site 3403)
city: Okayama
country: Japan
facility: Okayama University Hospital ( Site 3404)
city: Osaka
country: Japan
facility: Osaka International Cancer Institute ( Site 3410)
city: Osaka
country: Japan
facility: Osaka Metropolitan University Hospital ( Site 3412)
city: Cheongju-si
country: Korea, Republic of
facility: Chungbuk National University Hospital ( Site 3804)
state: Chungbuk
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center ( Site 3803)
state: Kyonggi-do
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital ( Site 3807)
state: Kyonggi-do
city: Suwon-si
country: Korea, Republic of
facility: The Catholic University Of Korea St. Vincent's Hospital ( Site 3800)
state: Kyonggi-do
city: Suwon
country: Korea, Republic of
facility: Ajou University Hospital ( Site 3813)
state: Kyonggi-do
city: Pusan
country: Korea, Republic of
facility: Pusan National University Yangsan Hospital ( Site 3802)
state: Kyongsangnam-do
city: Busan
country: Korea, Republic of
facility: Pusan National University Hospital ( Site 3805)
state: Pusan-Kwangyokshi
city: Daegu
country: Korea, Republic of
facility: Keimyung University Dongsan Hospital CRC room 1 ( Site 3814)
state: Taegu-Kwangyokshi
city: Jung-gu
country: Korea, Republic of
facility: Chungnam national university hospital ( Site 3806)
state: Taejon-Kwangyokshi
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 3812)
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center ( Site 3810)
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center ( Site 3811)
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital ( Site 3808)
city: Lembah Pantai
country: Malaysia
facility: University Malaya Medical Centre ( Site 3507)
state: Kuala Lumpur
city: Putrajaya
country: Malaysia
facility: National Cancer Institute-Radiotherapy and Oncology ( Site 3504)
state: Kuala Lumpur
city: Kuantan
country: Malaysia
facility: Hospital Tengku Ampuan Afzan ( Site 3506)
state: Pahang
city: George Town
country: Malaysia
facility: Hospital Pulau Pinang-Oncology, radiotherapy and palliat ( Site 3501)
state: Pulau Pinang
city: Kuching
country: Malaysia
facility: Sarawak General Hospital-Radiotherapy Unit ( Site 3508)
state: Sarawak
city: Mexico
country: Mexico
facility: Arké SMO S.A. de C.V. ( Site 0706)
state: Distrito Federal
city: Guadalajara
country: Mexico
facility: CIO - Centro de Inmuno-Oncología de Occidente ( Site 0700)
state: Jalisco
city: Oaxaca de Juarez
country: Mexico
facility: Centro de Investigacion Clinica de Oaxaca ( Site 0704)
state: Oaxaca
city: Oaxaca
country: Mexico
facility: Oaxaca Site Management Organization S.C. ( Site 0701)
city: Bydgoszcz
country: Poland
facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003)
state: Kujawsko-pomorskie
city: Warszawa
country: Poland
facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2000)
state: Mazowieckie
city: Bialystok
country: Poland
facility: Bialostockie Centrum Onkologii ( Site 2010)
state: Podlaskie
city: Gliwice
country: Poland
facility: Narodowy Instytut Onkologii - Oddzial w Gliwicach-II Klinika Radioterapi i Chemioterapii ( Site 2002)
state: Slaskie
city: LHospitalet de Llobregat
country: Spain
facility: Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2321)
state: Barcelona
city: Santiago de compostela
country: Spain
facility: CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2322)
state: La Coruna
city: Huelva
country: Spain
facility: Hospital Universitario Juan Ramon Jimenez-Oncología Medica ( Site 2323)
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2324)
city: Stockholm
country: Sweden
facility: Karolinska Universitetssjukhuset Solna ( Site 2401)
state: Stockholms Lan
city: Kaohsiung Niao Sung Dist
country: Taiwan
facility: Chang Gung Memorial Hospital at Kaohsiung ( Site 3905)
state: Kaohsiung
city: Tainan City
country: Taiwan
facility: National Cheng Kung University Hospital ( Site 3901)
state: Tainan
city: Tainan City
country: Taiwan
facility: Chi Mei Hospital - Liouying Branch ( Site 3909)
state: Tainan
city: Taipei City
country: Taiwan
facility: National Taiwan University Cancer Center (NTUCC) ( Site 3907)
state: Taipei
city: Changhua
country: Taiwan
facility: Changhua Christian Hospital ( Site 3904)
city: Hsinchu
country: Taiwan
facility: National Taiwan University Hospital - Hsinchu branch ( Site 3900)
city: New Taipei
country: Taiwan
facility: Far Eastern Memorial Hospital ( Site 3912)
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital-Chest ( Site 3910)
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital-Oncology ( Site 3908)
city: Taipei
country: Taiwan
facility: Mackay Memorial Hospital-Chest Medicine ( Site 3902)
city: Taipei
country: Taiwan
facility: Taipei Medical University Hospital ( Site 3903)
city: Taoyuan
country: Taiwan
facility: Chang Gung Medical Foundation-Linkou Branch-Clinic of Chest Medicine ( Site 3911)
city: Muang
country: Thailand
facility: Maharaj Nakorn Chiang Mai Hospital ( Site 4005)
state: Chiang Mai
city: Muang
country: Thailand
facility: Faculty of Medicine - Khon Kaen University ( Site 4002)
state: Khon Kaen
city: Bangkok
country: Thailand
facility: Faculty of Medicine Siriraj Hospital ( Site 4004)
state: Krung Thep Maha Nakhon
city: Dusit
country: Thailand
facility: Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 4006)
state: Krung Thep Maha Nakhon
city: Ratchathewi
country: Thailand
facility: Ramathibodi Hospital ( Site 4001)
state: Krung Thep Maha Nakhon
city: Mueang Lampang
country: Thailand
facility: Lampang Cancer Hospital ( Site 4000)
state: Lampang
city: HatYai
country: Thailand
facility: Songklanagarind hospital ( Site 4003)
state: Songkhla
city: Adana
country: Turkey
facility: Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2504)
city: Ankara
country: Turkey
facility: Hacettepe Universite Hastaneleri-oncology hospital ( Site 2501)
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi-Medical Oncology ( Site 2505)
city: Ankara
country: Turkey
facility: Ankara Bilkent Şehir Hastanesi ( Site 2500)
city: Izmir
country: Turkey
facility: I.E.U. Medical Point Hastanesi-Oncology ( Site 2503)
city: Hanoi
country: Vietnam
facility: Hanoi Oncology Hospital ( Site 4198)
state: Ha Noi
city: Hanoi
country: Vietnam
facility: K Hospital - National Cancer Hospital ( Site 4193)
state: Ha Noi
city: Tan Binh District
country: Vietnam
facility: Thong Nhat Hospital ( Site 4192)
state: Ho Chi Minh
city: Ho Chi Minh
country: Vietnam
facility: Cho Ray Hospital ( Site 4190)
city: Ho Chi Minh
country: Vietnam
facility: Ho Chi Minh City Oncology Hospital - Tan Phu Ward ( Site 4191)
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References: